speb/financial-data huggingface dataset:
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 304370000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -132894000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -132894000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 423108000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 234832200.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Operating Income: 345347000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 1147224000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 1181000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 445997000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 286481000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 280653000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 75227000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: 71494000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 21448200.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Tax Provision: -17889000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.30
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 801877000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: 71494000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 71494000.00
ADVENTHTL.NS income_statement (quarterly, 2025-12-31) — Write Off: -71494000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — +Operating Expense: 1870726000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 608691000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — +Total Revenue: 3875987000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 1154102000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 438923000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 438923000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 108421000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 108421000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 62383000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 62383000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 53943000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 53943000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Basic EPS: 11.71
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 0.53
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 50429000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -511936000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 539429000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 539429000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 259858000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 259858000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 301016000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 301016000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -7174000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: 10480000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 55623000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Change In Payable: 164748000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Change In Receivables: 127362000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: 380416000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 216945000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Common Stock: 539429000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 539429000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 9043953000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 9043953000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 2113492000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 2113492000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 995016000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 229734000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Current Assets: 648263000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 648263000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Current Debt: 4157735000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 4157735000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 4157735000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 4157735000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 21784582000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 21784582000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 14767000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 14767000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Depreciation: 141155000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 141155000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 295257000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 78876000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 295257000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 78876000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 53943000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 53943000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Diluted EPS: 11.71
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.53
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 631855000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 28701000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — EBIT: 1358649000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — EBIT: 227339000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — EBITDA: 1653906000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — EBITDA: 306215000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — End Cash Position: 267372000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: 1846674000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 1109236000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Goodwill: 5485415000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 5485415000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 5488277000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 5488277000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 16917942000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 16917942000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Gross Profit: 2880971000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 924368000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Interest Expense: 513552000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 111872000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 513552000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 111872000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -500732000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 13441000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Inventory: 36147000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 36147000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 17034175000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 17034175000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -3250901000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 62383000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 62383000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 3832487000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 3832487000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 3832487000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 3832487000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Long Term Equity Investment: 0.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 0.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 61187000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 61187000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Minority Interest: 1180937000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: 1180937000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Minority Interests: -22132000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Minority Interests: -7984000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Net Business Purchase And Sale: 0.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Net Debt: 7730364000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 7730364000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: 3139000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Net Income: 631855000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Net Income: 28701000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 631855000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 28701000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 653986000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 36685000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 631855000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 28701000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 631855000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 28701000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 842467000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 653987000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 36685000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Net Interest Income: -513552000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -111872000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: 2348306000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: 2348306000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -513552000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -111872000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Net Other Investing Changes: 60720000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Net PPE: 16917942000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 16917942000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -511936000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 3555676000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 3555676000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 2410427000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 2410427000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 1344446000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 420853000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Normalized Income: 392376564.32
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 97483800.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 1621172000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Operating Income: 1010245000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Operating Income: 315677000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Operating Revenue: 3875987000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 1154102000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 53942887.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 53942887.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Other Cash Adjustment Outside Changein Cash: -2000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 283510000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 283510000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 8504524000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 8504524000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 2862000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 2862000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: 500680000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 15986000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 15986000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: -1000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: -1000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 36313000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 25154000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 1575469000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 529815000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Other Properties: 14804450000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 14804450000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 1000000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 1000000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 41158000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 41158000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Other Special Charges: -195847000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Other Special Charges: 156758000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Payables: 438923000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Payables: 438923000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Pretax Income: 845097000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 115467000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 995016000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 229734000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 141155000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 78876000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Share Issued: 53942887.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 53942887.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Special Income Charges: 309460000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: -114638000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 9043953000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 9043953000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 3555676000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 3555676000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: 69981564.32
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -45855200.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Tax Provision: 191111000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 78782000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.23
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 201679000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 201679000.00
ADVENTHTL.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -133073000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Total Assets: 39930968000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 39930968000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 12876440000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 12876440000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Total Debt: 7990222000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 7990222000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 10224890000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 10224890000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Total Expenses: 2865742000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 838425000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 29706078000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 29706078000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 39282705000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 39282705000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 7921496000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 7921496000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Total Unusual Items: 309460000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: -114638000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: 309460000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -114638000.00
ADVENTHTL.NS balance_sheet (annual, 2026-03-31) — Working Capital: -21136319000.00
ADVENTHTL.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: -21136319000.00
ADVENTHTL.NS income_statement (annual, 2026-03-31) — Write Off: -113613000.00
ADVENTHTL.NS income_statement (quarterly, 2026-03-31) — Write Off: -42120000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -1374110000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 813550000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -8480000.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Amortization: 79980000.00
ADVENZYMES.NS cash_flow (annual, 2022-03-31) — Amortization Cash Flow: 79980000.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Basic Average Shares: 111777150.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Basic EPS: 10.70
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 1123940000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 819940000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 1853610000.00
ADVENZYMES.NS cash_flow (annual, 2022-03-31) — Common Stock Dividend Paid: -118600000.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Diluted Average Shares: 111869256.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Diluted EPS: 10.68
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Dividends Payable: 1080000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 650000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 347250000.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 207190000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 890540000.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Impairment Of Capital Assets: 0.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Interest Income: 4040000.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 4040000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 530010000.00
ADVENZYMES.NS cash_flow (annual, 2022-03-31) — Long Term Debt Issuance: 6740000.00
ADVENZYMES.NS cash_flow (annual, 2022-03-31) — Long Term Debt Payments: -23200000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 2341960000.00
ADVENZYMES.NS cash_flow (annual, 2022-03-31) — Net Business Purchase And Sale: 0.00
ADVENZYMES.NS cash_flow (annual, 2022-03-31) — Net Other Financing Charges: -211250000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 10680000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 81280000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Other Payable: 232160000.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Other Special Charges: -11500000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 98970000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
ADVENZYMES.NS cash_flow (annual, 2022-03-31) — Purchase Of Business: 0.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 558410000.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 42380000.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 42380000.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Research And Development: 6470000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 44770000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 9072970000.00
ADVENZYMES.NS cash_flow (annual, 2022-03-31) — Sale Of Investment: 220990000.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 147660000.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 354850000.00
ADVENZYMES.NS cash_flow (annual, 2022-03-31) — Short Term Debt Issuance: 0.00
ADVENZYMES.NS cash_flow (annual, 2022-03-31) — Short Term Debt Payments: -64920000.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 11590000.00
ADVENZYMES.NS balance_sheet (annual, 2022-03-31) — Work In Process: 303540000.00
ADVENZYMES.NS income_statement (annual, 2022-03-31) — Write Off: 9210000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — +Operating Expense: 2593180000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — +Total Revenue: 5403820000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 242210000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 1003410000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -1620480000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 821310000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -15470000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Amortization: 73040000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Amortization Cash Flow: 73040000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 50000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 111815999.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Basic EPS: 9.45
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 2673550000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 1280500000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -381810000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Capital Expenditure Reported: 0.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 202600000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 223650000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 964200000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 4842810000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Cash Dividends Paid: -125420000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 363680000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 600520000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Change In Inventory: 7550000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: 15460000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: 22860000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Change In Payable: 60280000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -101340000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -3410000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Changes In Cash: -1836170000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Common Stock: 223650000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Common Stock Dividend Paid: -125420000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 12350690000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Common Stock Issuance: 1420000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 156090000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 1427680000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Current Assets: 7210560000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 56820000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Current Debt: 54400000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 111220000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 775660000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 37190000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Depreciation: 277250000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 350290000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 350290000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 277250000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 111815999.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Diluted EPS: 9.45
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 1056390000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 1170000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — EBIT: 1428090000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — EBITDA: 1778380000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Effect Of Exchange Rate Changes: 126620000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — End Cash Position: 964200000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 1650000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: -257980000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 286530000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: 1021810000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: 21980000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: 7990000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 218260000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Goodwill: 3208530000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 3817310000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 1018880000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 4508700000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Gross Profit: 3976140000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Impairment Of Capital Assets: 6870000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Interest Expense: 24210000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 24210000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Interest Income: 94830000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 94830000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -24210000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 78700000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Inventory: 1239900000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 12483080000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -2981810000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 1700000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Issuance Of Capital Stock: 1420000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Issuance Of Debt: 26220000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 571740000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 145780000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 77990000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 223770000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Long Term Debt Issuance: 0.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: -3220000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 5060000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 2500370000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Minority Interest: 491020000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Minority Interests: 17730000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: 1420000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: -1070000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Net Income: 1056390000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 1056390000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 1038660000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 1056390000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 1056390000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 1403880000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 1038660000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Net Intangibles Purchase And Sale: -760000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Net Interest Income: 60050000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -2681740000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: 23000000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: -3220000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: 60050000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Net Other Financing Charges: -68000000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Net Other Investing Changes: 500000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Net PPE: 2888220000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -378510000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: 26220000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 8533380000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 113420000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 372270000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 5060000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 62410000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 1869930000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Normalized Income: 1124123227.20
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 1403620000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Operating Income: 1382960000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Operating Revenue: 5403820000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 111824075.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Other Cash Adjustment Outside Changein Cash: 200000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 9680000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 105220000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 12127040000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 608780000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: -21140000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 850000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 39400000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 752440000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Other Payable: 292630000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Other Properties: 2732130000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 10680000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 3878610000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Other Special Charges: 48130000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Payables: 550850000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 98160000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Pretax Income: 1403880000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 4200000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Purchase Of Intangibles: -760000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -2681740000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -381050000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 627530000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 1427680000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 350290000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 62360000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 62360000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -3220000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Research And Development: 8090000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 5920000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 10022770000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 0.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 2540000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 160820000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 379080000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Share Issued: 111824075.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Short Term Debt Issuance: 26220000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Special Income Charges: -64310000.00
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Stock Based Compensation: 0.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 12350690000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 8533380000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: -23816772.80
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Tax Provision: 365220000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.26
ADVENZYMES.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -366390000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Total Assets: 14218470000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 12428680000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Total Debt: 334990000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 12841710000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Total Expenses: 4020860000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 1376760000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 7007910000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 601100000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 10570000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 14840000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Total Unusual Items: -91550000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -91550000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Work In Process: 325840000.00
ADVENZYMES.NS balance_sheet (annual, 2023-03-31) — Working Capital: 6434900000.00
ADVENZYMES.NS income_statement (annual, 2023-03-31) — Write Off: 9310000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — +Operating Expense: 2912380000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — +Total Revenue: 6234770000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 157590000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 985680000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -1880840000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 821310000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -12360000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Amortization: 77400000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 77400000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 60000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 111824075.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Basic EPS: 11.92
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 964200000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 1399310000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -473130000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Capital Expenditure Reported: -49500000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 221960000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 223650000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 1137510000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 5479720000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -567120000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 717480000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 420030000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -238340000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: -31440000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: -1280000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Change In Payable: -39410000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Change In Receivables: 7730000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -262530000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 174820000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Common Stock: 223650000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Common Stock Dividend Paid: -567120000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 13241280000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 0.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 307370000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 1594110000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Current Assets: 8094710000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 63400000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Current Debt: 181520000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 244920000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 1063570000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 196750000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Depreciation: 275020000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 352420000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 352420000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 275020000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 111879311.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Diluted EPS: 11.92
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 1333050000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 1590000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — EBIT: 1907490000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — EBITDA: 2259910000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: -1510000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — End Cash Position: 1137510000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 1650000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -592380000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 357870000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 940560000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -108480000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: 2300000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 240710000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Goodwill: 3252950000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 3835810000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 998040000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 4953490000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Gross Profit: 4640660000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Impairment Of Capital Assets: 0.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Interest Expense: 29280000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 29280000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Interest Income: 133260000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 133260000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -29250000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 129390000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Inventory: 1484550000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 13492400000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -646490000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 1710000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 0.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 127030000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 580980000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 158560000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 69600000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 228160000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -6480000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 8860000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 2665830000.00